Probiotic bacteria-derived effector molecules and their impact on the host in health and disease

0565176 - MBÚ 2023 RIV CH eng J - Journal Article
Górska, S. - Schwarzer, Martin - Schabussová, I. - Zawilak-Pawlik, A.M. - Sandström, C.
Probiotic bacteria-derived effector molecules and their impact on the host in health and disease.
Frontiers in Microbiology. Roč. 13, 29 November (2022), č. článku 108946. ISSN 1664-302X. E-ISSN 1664-302X
R&D Projects: GA ČR GA19-02261S; GA MŠMT(CZ) 8J20AT011
Institutional support: RVO:61388971
Keywords : Bifidobacterium * Lactobacillus * probiotics * post-biotics * vesicles * exopolysaccharides * peptidoglyc
OECD category: Microbiology
Impact factor: 5.2, year: 2022
Method of publishing: Open access
https://www.frontiersin.org/articles/10.3389/fmicb.2022.1089461/full

Bacteria are one of the main modulators of the physiology and the immune system of the host organism (Tlaskalova-Hogenova et al., 2011). Changes in the composition and abundance of bacterial communities, especially, but not exclusively, in the gastrointestinal tract are believed to be a key factor in the host's susceptibility to various diseases (e.g., allergy, inflammatory bowel disease, irritable bowel syndrome, or necrotizing enterocolitis). It is not surprising that prophylactic/therapeutic approaches to modulate the microbiota composition, for example by probiotic bacteria, are being pursued. Along these lines, the history and diversity of probiotics, as well as outlines of conventional in vitro assays and in vivo models, have been in-depth reviewed by Milner et al. Despite the interest in probiotics as food or supplement use in the clinic, there are huge discrepancies observed in the outcomes of such studies. Duboux et al. suggest that these differences, besides being attributed to variations in the bacterial species and clinical trial protocols, target population, probiotic dosage, or outcome parameters measured, may stem from the methods used to produce the live bioactive ingredients. In their review, the authors suggest that the implementation of molecular level quality controls based on validated probiotic niche factors and effector molecules could improve the functional reliability of probiotic products.
Permanent Link: https://hdl.handle.net/11104/0336681